TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Stroke risk after TAVR still higher for woman as ‘sex paradox’ lives on
By tracking sex-related differences after TAVR, researchers hope to refine patient selection strategies and optimize care for both men and women.
TAVR valve for AR , a recent Edwards acquisition, delivers long-term value
The J-Valve System is associated with positive 10-year outcomes for patients with severe AR, according to new research out of China. It also performs well in patients with severe AS.
Medtronic SVP Nina Goodheart to retire after nearly 20 years in cardiovascular care
Nina Goodheart, the president of Medtronic’s structural heart and aortic business, has announced her retirement.
Patients with paradoxical low-flow, low gradient AS linked to higher mortality rate after TAVR
Patients with this specific subtype of severe aortic stenosis, which can sometimes be challenging to diagnose, face a number of additional risks.
Abbott executive who led TAVR, Tendyne divisions announces exit
Chris Waddell, a medtech executive focused on various structural heart technologies, is leaving Abbott after several years to "recharge" and pursue a new opportunity.

Stroke risk after TAVR still higher for woman as ‘sex paradox’ lives on

By tracking sex-related differences after TAVR, researchers hope to refine patient selection strategies and optimize care for both men and women.

TAVR valve for AR , a recent Edwards acquisition, delivers long-term value

The J-Valve System is associated with positive 10-year outcomes for patients with severe AR, according to new research out of China. It also performs well in patients with severe AS.

Medtronic SVP Nina Goodheart to retire after nearly 20 years in cardiovascular care

Nina Goodheart, the president of Medtronic’s structural heart and aortic business, has announced her retirement.

old woman or doctor shaking hands with patient

Patients with paradoxical low-flow, low gradient AS linked to higher mortality rate after TAVR

Patients with this specific subtype of severe aortic stenosis, which can sometimes be challenging to diagnose, face a number of additional risks.

Abbott executive who led TAVR, Tendyne divisions announces exit

Chris Waddell, a medtech executive focused on various structural heart technologies, is leaving Abbott after several years to "recharge" and pursue a new opportunity.

Robotic aortic valve replacement (RAVR) is a new minimally invasive treatment option for symptomatic severe aortic stenosis (AS) that uses advanced robotic surgical systems. It has already started gaining momentum as an alternative to both surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR).

Robotic cardiac surgery building momentum thanks to RAVR, other breakthroughs

The sky may be the limit for robotic cardiac surgery in 2026 and beyond.

The DurAVR TAVR system from Anteris Technologies

Medtronic invests $90M in medtech company behind one-of-a-kind TAVR tech

Anteris Technologies is known for its biomimetic transcatheter heart valve, the DurAVR THV System. The device is the first of its kind and has gained considerable attention as the TAVR market continues to grow.

Abbott’s medtech sales climbed in Q4 thanks to strength of heart devices

Abbott pointed to double-digit growth for its Navitor TAVR valve as well as big gains for the TriClip and MitraClip devices. The company also shared positive sales figures for its EP, heart failure and rhythm management portfolios.